Recent advances inEbolavirusvaccine development

Aerosolized Ebola vaccine protects primates and elicits lung-resident T cell responses

“…The low expression of CD107a might also be explained by the transient nature of its expression on the surface of the cell, which is followed by its internalization (45). Studies on experimental filovirus vaccines to date have failed to directly compare the performance of different vaccine platforms, instead relying on published results generated under different conditions to draw comparisons (47). This study provides a side-by-side evaluation of antibody-and cell-mediated responses to 2 very different vaccines: a recombinant paramyxovirus vector administered to the respiratory tract and VRP, administered via the i.m.…”

Successful Treatment of Ebola Virus–Infected Cynomolgus Macaques with Monoclonal Antibodies

“…Recent advances in vaccine development against EBOV resulted in the identification of several successful immunization strategies to mount protective immune responses to macaques (4). The vesicular stomatitis virus (VSV)-based Ebola vaccine resulted in 50% protection in rhesus macaques when administered 20 to 30 min after a lethal challenge with EBOV (5).…”

Mice Orally Immunized with a Transgenic Plant Expressing the Glycoprotein of Crimean-Congo Hemorrhagic Fever Virus

“…A CCHFV DNA vaccine expressing the viral glycoprotein elicits in some vaccinated mice neutralizing antibodies that can be precipitated with radiolabeled viruses (43). Although an inactivated CCHFV vaccine could reduce CCHF outbreaks (36), there is a stigma attached to using attenuated vaccines due to a fear of reversion of virulence or possible reversion to wild-type virus (38). Hence, the use of recombinant subunit vaccines renders a remarkable benefit to immunization programs.…”